"Hypercholesterolemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Descriptor ID |
D006937
|
| MeSH Number(s) |
C18.452.584.500.500.396
|
| Concept/Terms |
Hypercholesterolemia- Hypercholesterolemia
- Hypercholesterolemias
- High Cholesterol Levels
- Cholesterol Level, High
- Cholesterol Levels, High
- High Cholesterol Level
- Level, High Cholesterol
- Levels, High Cholesterol
- Elevated Cholesterol
- Cholesterol, Elevated
- Cholesterols, Elevated
- Elevated Cholesterols
- Hypercholesteremia
- Hypercholesteremias
|
Below are MeSH descriptors whose meaning is more general than "Hypercholesterolemia".
Below are MeSH descriptors whose meaning is more specific than "Hypercholesterolemia".
This graph shows the total number of publications written about "Hypercholesterolemia" by people in this website by year, and whether "Hypercholesterolemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 2 | 4 |
| 2003 | 5 | 1 | 6 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypercholesterolemia" by people in Profiles.
-
Reducing Disparities in Cholesterol Control. JAMA. 2022 08 23; 328(8):714-716.
-
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1):9-20.
-
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020 05 12; 75(18):2297-2308.
-
Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019 07 09; 140(2):103-112.
-
Differences in plasma levels of long chain and very long chain ceramides between African Americans and whites: An observational study. PLoS One. 2019; 14(5):e0216213.
-
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 11 29; 379(22):2097-2107.
-
Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. Biomed Pharmacother. 2018 09; 105:992-996.
-
Evolocumab: Considerations for the Management of Hyperlipidemia. Curr Atheroscler Rep. 2018 03 06; 20(4):17.
-
ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target. Biochem Pharmacol. 2018 05; 151:188-200.
-
Cholesterol Control Among Uninsured Adults Did Not Improve From 2001-2004 to 2009-2012 as Disparities With Both Publicly and Privately Insured Adults Doubled. J Am Heart Assoc. 2017 Nov 02; 6(11).